

Amendment Statement of Principles

concerning

HYPOPITUITARISM  
(Balance of Probabilities)

(No. 54 of 2022)

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(3) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 29 April 2022

|  |
| --- |
| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of: |
| Professor Terence Campbell AM  Chairperson |

Contents

1 Name 3

2 Commencement 3

3 Authority 3

4 Amendment 3

1. Name

This is the Amendment Statement of Principles concerning *hypopituitarism* *(Balance of Probabilities)* (No. 54 of 2022).

1. Commencement

This instrument commences on 30 May 2022.

1. Authority

This instrument is made under subsections 196B(3) and (8) of the *Veterans' Entitlements Act 1986*.

1. Amendment

The Statement of Principles concerning *hypopituitarism (Balance of Probabilities)* (No. 12 of 2019) (Federal Register of Legislation No. F2019L00012) is amended in the following manner:

|  |  |
| --- | --- |
| **Section** | **Amendment** |
| *9(13)* | *Replace the existing factor in subsection 9(13) with the following*:  taking an immune checkpoint inhibitor or an interferon within the one year before the clinical onset of hypopituitarism;  Note: ***immune checkpoint inhibitor*** is defined in the Schedule 1 - Dictionary. |
| *9(27)* | *Replace the existing factor in subsection 9(27) with the following*:  taking an immune checkpoint inhibitor or an interferon within the one year before the clinical worsening of hypopituitarism;  Note: ***immune checkpoint inhibitor*** is defined in the Schedule 1 - Dictionary. |
| *Schedule 1 – Dictionary* | *Replace the existing definition of "immune checkpoint inhibitor" with the following:*  ***immune checkpoint inhibitor*** means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab. |